Thursday, April 13, 2017

The Inaugural Institute of Cannabis Research (ICR) Conference: April 28-30, 2017



The Institute of Cannabis Research (ICR) at Colorado State University-Pueblo has released the program for its international, multidisciplinary cannabis research conference set for April 28-30, on the Colorado State University-Pueblo campus.  


The ICR conference will celebrate a myriad of research and intellectual pursuits from internationally renowned speakers and pioneering cannabis scholars. The preliminary program provides information on more than 70 scheduled presentations from 100+ state, national, and international cannabis researchers from private research organizations, prominent universities, state and national government agencies, and industry representatives.





International cannabis scholars from as far away as Australia, Israel, and Italy are expected to attend, along with cannabis researchers from Arizona, California, Colorado, Illinois, Maryland, Massachusetts, Nebraska, New Mexico, New York, Oregon, South Dakota, and Washington. Governmental experts from the National Institute on Drug Abuse in Washington, D.C., the Colorado Department of Public Health and Environment, and the National Drug Research Institute of Australia also will serve as conference presenters.


Presentation & Research Topics For The Scientific, Medical, Industrial, Legal, Economic, and Social Elements of Cannabis



Research work to be presented at the conference represents a diversity of disciplines from a wide variety of presenters.  Numerous presentations will address medical issues related to cannabis, including cannabis and particular diseases.  Other work describes neuroscience work in animal models and work related to hemp.  Presentations will also address social, economic, and legal issues related to cannabis.  Work will be presented by academic scholars; practicing physicians and other health care workers; governmental scientists and regulators; attorneys; engineers and technicians working for medical marijuana companies.  
Presentations addressing medical issues related to cannabis will include cannabis and particular diseases (e.g. hospital emergency room data; cannabidiol and the treatment of Parkinson’s Disease; the relationship of marijuana usage and patients hospitalized with acute myocardial infarction; and cannabis studies addressing post traumatic stress disorder, multiple sclerosis, inflammatory bowel disease, and epilepsy).  Other work describes neuroscience work in animal models (e.g. effects of cannabinoid intake during pregnancy on neurotransmitters in rat offspring, and neuro-receptor studies in mice that relate to memory and fear).
Sessions also will discuss work related to hemp (e.g. applications of industrial hemp for remediation; hemp as a reinforcing material for 3D printers; and genetic analysis of hemp varieties from Europe, California and Colorado) as well as social, economic, and legal issues related to cannabis (e.g. land, water, and energy use issues; middle and high school education initiatives; perspectives from hospice and other caregivers; certain economic impacts in states such as Colorado and Washington; and a variety of survey results).  

Cannabis Experts Take Center Stage

Dr. Hart
The conference will open at 5 p.m. on Friday, April 28, with a plenary lecture by Dr. Carl Hart, chair of the Department of Psychology at Columbia University and Dirk Ziff Professor of Psychology in the Departments of Psychology and Psychiatry. He has published numerous scientific articles in neuropsychopharmocology and its impact on public policy and drug abuse treatment.          
On Saturday, Dr. Raphael Mechoulam, who is considered “the father of cannabis research,”will present the inaugural Mechoulam Lecture, which will commemorate the groundbreaking discoveries that have made contemporary cannabis science possible. Mechoulam is professor in the Department of Medicinal Chemistry at the Institute of Drug Research at Hebrew University in Israel. The Bulgarian born professor is a pioneer in cannabis research; after first isolating and analyzing the most important compounds in cannabis, his research lab led to the discovery of cannabinoid receptors, and later the endocannabinoid system.  His ground-breaking discoveries, beginning early in the 1960’s, are the basis for nearly every piece of research conducted today.




On Saturday evening, CSU-Pueblo will sponsor a reception at El Pueblo Museum, 301 N. Union Ave., for attendees and invited guests to meet the CSU-Pueblo faculty directly involved in both the state-funded ICR research and the Pueblo County impact studies.
Dr. Makriyannis
 
The conference will close late Sunday morning with a plenary lecture by Dr. Alexandros Makriyannis, the George D. Behrakis Endowed Chair in Pharmaceutical Biotechnology and Director of the Center for Drug Discovery at Northeastern University in Boston, Mass. Makriyannis will also serve as guest editor of the conference proceedings to be published in summer 2017.

Register Now For This Sublime Cannabis Research Conference

To view the detailed conference schedule and register for the conference, visit the website at www.csupueblo.edu/ICR.


For information on the conference, please contact ICR Interim Managing Director Jennifer Mullen, at jen.mullen@csupueblo.edu
Dr. Raphael Mechoulam


Colorado State University - Pueblo is committed to excellence, setting the standard for regional comprehensive universities in teaching, research, and service by providing leadership and access for its region, while maintaining its commitment to diversity.
(Press Release Provided by CSU-Pueblo- 2017)

Friday, April 7, 2017

Medical Cannabis Advisory Board Recommendations Empower Medical Cannabis Community

 
MEDIA RELEASE -Friday, April 7th 2017
LECUA_thc_cbd.png




The LECUA Patient’s Coalition Of New Mexico has provided the New Mexico Department of Health Medical Cannabis Program 20 Petitions for the Medical Cannabis Advisory Board to review and address at the MCAB Hearing 10am - Friday - April 7th - 2017.  
Petitions Authored & Organized By Jason Barker
- Medical Cannabis Patient & Organizer with the
LECUA Patient’s Coalition Of New Mexico

All Petitions Can Be Viewed Online At:
LECUA NM MCP MCAB Petitions:
http://lecuanmmcpmcabpetitions.blogspot.com/

These Petitions Reviewed By The MCAB, Isn’t A Medical Cannabis Case…
It’s A HealTHCare Case.

Petition Action Vote (Y/N)
2017‐012 Add autism as a condition Recommended to add to MCP 3-0
2017‐013 Add anxiety as a condition Recommended to add to MCP 3-1
2017‐014 Add depression Recommended to add to MCP 4-0
2017‐015 Add Concussions, CTE and TBI as conditions Tabled
2017‐016 Add diabetes 0-4
2017‐017 Add Dystonia Recommended to add to MCP 4-0
2017‐018 Add Migraines Recommended to add to MCP 4-0
2017‐019 Add Rheumatoid Arthritis Recommended to expand terms 4-0
(Petition 2017-019 (Title Was TO BE) : Requesting The Inclusion Of A New Medical Condition: Rheumatoid Arthritis (RA) To Include:
There are more than 100 different forms of arthritis and related diseases. The most common types include osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), fibromyalgia and gout.   *Printing Error at copy place used wrong cover page…)

2017‐020 Sleep Disorders Recommended to add to MCP 4-0
2017‐021 Substance Abuse Disorder Tabled
2017‐022 Patient Run Collectives Recommended to add to MCP 4-0
2017-005 Change/increase possession limit to 16 oz Recommended to add to MCP 4-0
2017-009 Removal of Max THC Content Recommended Removal of Cap   4-0

Per legal counsel’s input petitions numbered 1,2,3,4, and 11 would require statutory changes or are not covered under the duties of the MCAB and will not be discussed.
2017-001 Add Veteran Status as a Qualifying Condition
2017-002 Allow any chronic condition to be a qualifying condition
2017-003 Change LECUA to give MCAB more authority (increase membership)
2017-004 Change LECUA to make renewals every three years
2017-011 Add definition of Medical Treatment definition to LECUA and add Adequate
Supply
Petitions 6, 8,10 and 23 concern the licensed producers and would require statutory changes and are not covered under the duties of the MCAB and will not be discussed.
2017-006 Allow PPL holders to use manufacturers for conversion of product.
2017-008 Remove CBD plants from producer plant count (This is a regulatory change).
2017-010 Increase plants for licensed producers (This is a regulatory change).
2017-023 Develop MCP education and research components

All Petitions Can Be Viewed Online At:
LECUA NM MCP MCAB Petitions
http://lecuanmmcpmcabpetitions.blogspot.com/


Petitions provided to the Medical Cannabis Advisory Board (MCAB)

  1. Petition Pertaining to the Medical Treatment; Adequate Supply: Limit of 230 Units per 3 months changed/increased

   II. Petition Pertaining to the Medical Treatment; Adequate Supply:
            Potency Cap of THC for  Concentrates Removed

   III. Petition Pertaining to the Medical Treatment; Adequate Supply:
            Personal Production License Plant Increase & PPL Collectives  
   IV. Petition Pertaining to the Medical Treatment; Adequate Supply: LNPP Plant Count Increase

   V. Petition Pertaining to the Medical Treatment; Adequate Supply:
            Remove CBD from Plant Count

   VI. Petition Pertaining to the Condition to Add: Anxiety Disorder

   VII. Petition Pertaining to the Condition to Add: Autism Spectrum Disorder

    VIII. Petition Pertaining to the Condition to Add: Concussion, CTE, & TBI

    IX. Petition Pertaining to the Condition to Add: Depression (clinical)

    X. Petition Pertaining to the Condition to Add: Diabetes Mellitus

    XI. Petition Pertaining to the Condition to Add: Dystonia
    XII. Petition Pertaining to the Condition to Add: Migraine
    XIII. Petition Pertaining to the Condition to Add: Rheumatoid Arthritis

    XIV. Petition Pertaining to the Condition to Add: Substance Abuse Disorder
    XV. Petition Pertaining to the Medical Treatment; Exception To Qualifying Conditions To Add:
            A Person’s Status as a Veteran

    XVI. Petition Pertaining to the Medical Treatment; Increase MCAB membership
            (Medical cannabis advisory board responsibilities and duties)

   XVII. Petition Pertaining to the Medical Treatment; ADA language for Section 8 of LECUA
            (Medical cannabis registry identification cards)    

  XVIII. Petition Pertaining to the Medical Treatment; Medical Cannabis 3 yr registry
            identification cards
Presumptive eligibility and once a patient is accepted into the program,  registry and PPL identification cards should be set at a 3 renewal basis. The Department can then do yearly address verification by mail all while maintaining safe access to medical cannabis.

  XIX. Petition Pertaining to the Medical Treatment; Medical Cannabis Program Research
            & Education Established

  XX. Petition Pertaining to the Condition to Add: Insomnia / Sleep Disorders


Next MCAB Meeting Tentative Date of Nov 3rd 2017 at 10am